Breast CancerPhase 3NCT01376349
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
A Phase 3 study testing prasterone in people with Breast Cancer and Gynecologic Cancer, run by Alliance for Clinical Trials in Oncology at 280 sites in United States.
Trial summary
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors. PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Gynecologic Cancer
- What is being tested?
- prasterone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 464 participants
- Where
- 280 sitesUnited States
- Study dates
- Jul 2011to Nov 2017
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Postmenopausal women with a history of breast or gynecologic cancer (currently no evidence of disease). Note: Postmenopausal status will be determined by the following criteria:
- 12 months without a period or bilateral oophorectomy or complete chemical ovarian suppression for the past 12 months with continued suppression planned throughout the course of the study
- menopausal status will be determined by an FSH and an estradiol value in the postmenopausal range (generally FSH > 40IU/L and estradiol < 10 pg/ml, depending on laboratory) if:
- 9 months without a period or
- post hysterectomy with at least one ovary remaining and less than 55 years old. Note: if age 55 or older with these criteria, then menopausal status does not need to be determined by labs
Show all 15Show fewer
- Significant vaginal complaints. Note: Defined as persistent vaginal dryness and/or pain with intercourse (dyspareunia) of sufficient severity to make a patient desire therapeutic intervention.
- Eligibility questionnaire response must be moderate or worse levels of severity on one of the two symptoms, either dryness or dyspareunia. The protocol contains more information.
- Vaginal symptoms must have been present ≥ 2 months prior to randomization.
- Life expectancy > 12 months.
- Ability to complete questionnaires by themselves or with assistance.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
- The patient must provide informed written consent.
- Willing to return to the enrolling institution for follow-up.
- Willing to provide blood samples for correlative research purposes.
Who cannot join
- Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤ 2 months prior to randomization or plans to initiate or discontinue any of these medications during the 12-week study.
- Current diagnosis of an active vaginal infection, if symptoms of vaginal infection, this must be ruled out (ie, foul discharge, fever).
- Concurrent chemotherapy (long term adjuvant herceptin, lapatanib, and/or bevacizumab is allowed.
- Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Water-based lubricants (such as KY jelly) are allowed during sexual intercourse.
- Use of any daily non-hormonal vaginal preparations ≤ 1 week prior to study entry.
- Exception: Daily water-based lubricants for sexual intercourse. Note: Patients who stop agent may be enrolled after one week.
Show all 23Show fewer
- Current (≤ 4 weeks prior to randomization), or planned during the study period, use of any estrogen product or any kind of hormonal vaginal product including bioidentical hormones, estriol or any androgen product.
- Use of pharmacologic soy or phytoestrogen preparations (Dietary intake of soy - ie milk is acceptable).
- On a placebo controlled trial for endocrine therapy.
- Prior or concurrent pelvic radiation therapy.
- Prior radical pelvic surgery, specifically vaginectomy or pelvic exenteration (TAH/BSO) is allowed).
- Diagnosis of any of the following conditions within the past five years:
- Essential vulvodynia
- Vulvar vestibulitis
- Bartholin cyst/abscess
- History of Bartholin gland surgery
- Lichen sclerosis
- Lichen planus of the vulvovaginal region
- Desquamative vaginitis
- History or current diagnosis of any of the following conditions:
- Vulvar or vaginal dysplasia
- Vaginal prolapse
- Women of childbearing potential, premenopausal women.
Trial locations and contacts
280 sites in 1 country.
280 sites in 1 country
United States280 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Lovelace Medical Center - Downtown
Albuquerque, New Mexico, 87102
Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
MeritCare Bemidji
Bemidji, Minnesota, 56601
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Study site
Bettendorf, Iowa, 52722
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
St. Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Illinois CancerCare - Canton
Canton, Illinois, 61520
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center - West Lakes
Clive, Iowa, 50325
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Herbert D. Kerman Regional Oncology Center - Daytona Beach
Daytona Beach, Florida, 32114
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80222
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Essentia Health - Duluth Clinic
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Community Cancer Center
Elyria, Ohio, 44035
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
MeritCare Broadway
Fargo, North Dakota, 58102
Dakota Cancer Institute at Dakota Clinic - South University
Fargo, North Dakota, 58103
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Illinois CancerCare - Havana
Havana, Illinois, 62644
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
St. Peter's Hospital
Helena, Montana, 59601
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
Hawaii Medical Center - East
Honolulu, Hawaii, 96817
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
St. Francis Hospital Cancer Care Services
Indianapolis, Indiana, 46237
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Castle Medical Center
Kailua, Hawaii, 96734
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Howard Community Hospital
Kokomo, Indiana, 46904
Franciscan Skemp Healthcare - La Crosse Campus
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Fairfield Medical Center
Lancaster, Ohio, 43130
Carolina Blood and Cancer Care Associates, PA
Lancaster, South Carolina, 29720
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
University of New Mexico Cancer Center - South
Las Cruces, New Mexico, 88011
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Kauai Medical Clinic
Lihue, Hawaii, 96766
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Littleton Adventist Hospital
Littleton, Colorado, 80122
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80501
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
Immanuel St. Joseph's
Mankato, Minnesota, 56002
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology - Maplewood
Maplewood, Minnesota, 55109
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
Cancer Center of Kansas, PA - McPherson
McPherson, Kansas, 67460
Idaho Urologic Institute, PA
Meridian, Idaho, 83642
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Illinois CancerCare - Monmouth
Monmouth, Illinois, 61462
OSF Holy Family Medical Center
Monmouth, Illinois, 61462
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Knox Community Hospital
Mount Vernon, Ohio, 43050
New Ulm Medical Center
New Ulm, Minnesota, 56073
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Illinois CancerCare - Community Cancer Center
Normal, Illinois, 61761
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Immanuel Medical Center
Omaha, Nebraska, 68122
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Willamette Falls Hospital
Oregon City, Oregon, 97045
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
Parker Adventist Hospital
Parker, Colorado, 80138
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Illinois CancerCare - Pekin
Pekin, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare - Peru
Peru, Illinois, 61354
Illinois Valley Community Hospital
Peru, Illinois, 61354
Michiana Hematology Oncology PC - Plymouth
Plymouth, Indiana, 46563
St. Joseph Mercy Oakland
Pontiac, Michigan, 48341-2985
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Southern Ohio Medical Center Cancer Center
Portsmouth, Ohio, 45662
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Illinois CancerCare - Princeton
Princeton, Illinois, 61356
St. Mary - Corwin Regional Medical Center
Pueblo, Colorado, 81004
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Humphrey Cancer Center at North Memorial Outpatient Center
Robbinsdale, Minnesota, 55422-2900
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Carolina Blood and Cancer Care
Rock Hill, South Carolina, 29732
Mercy Clinic Cancer and Hematology - Rolla
Rolla, Missouri, 65401
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Seton Cancer Institute at Saint Mary's - Saginaw
Saginaw, Michigan, 48601
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Lakeside Cancer Specialists, PLLC
Saint Joseph, Michigan, 49085
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Cancer Center
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
St. Francis Cancer Center at St. Francis Medical Center
Shakopee, Minnesota, 55379
St. Nicholas Hospital
Sheboygan, Wisconsin, 53081
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51102
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Sanford Cancer Center at Sanford USD Medical Center
Sioux Falls, South Dakota, 57117-5039
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Memorial Hospital of South Bend
South Bend, Indiana, 46601
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Illinois CancerCare - Spring Valley
Spring Valley, Illinois, 61362
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65804
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Geisinger Medical Group - Scenery Park
State College, Pennsylvania, 16801
Lakeview Hospital
Stillwater, Minnesota, 55082
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Flower Hospital Cancer Center
Sylvania, Ohio, 43560
North Suburban Medical Center
Thornton, Colorado, 80229
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Toledo Hospital
Toledo, Ohio, 43606
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Medical University of Ohio Cancer Center
Toledo, Ohio, 43614
CCOP - Toledo Community Hospital
Toledo, Ohio, 43617
St. Anne Mercy Hospital
Toledo, Ohio, 43623
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98664
Northwest Cancer Specialists at Vancouver Cancer Center
Vancouver, Washington, 98684
Ridgeview Medical Center
Waconia, Minnesota, 55387
Maui Memorial Medical Center
Wailuku, Hawaii, 96793
Pacific Cancer Institute - Maui
Wailuku, Hawaii, 96793
St. John Macomb Hospital
Warren, Michigan, 48093
Fulton County Health Center
Wauseon, Ohio, 43567
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Michiana Hematology Oncology PC - La Porte
Westville, Indiana, 46391
Exempla Lutheran Medical Center
Wheat Ridge, Colorado, 80033
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 18711
Willmar Cancer Center at Rice Memorial Hospital
Willmar, Minnesota, 56201
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Minnesota Oncology - Woodbury
Woodbury, Minnesota, 55125
United States Air Force Medical Center - Wright-Patterson
Wright-Patterson Air Force Base, Ohio, 45433-5529
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors.
PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
Read the detailed description
Primary Goal:
- To determine the effectiveness of two doses of daily vaginal prasterone (dehydroepiandrosterone [DHEA]) versus placebo for alleviation of the most bothersome vaginal symptom (vaginal dryness or dyspareunia) over 12 weeks.
Exploratory Goals:
- To evaluate any toxicities arising from DHEA in this patient population. (Exploratory)
- To evaluate the impact of vaginal DHEA on negative sexual thoughts, sexual function and urologic symptoms. (Exploratory)
- To explore the role of psychologic (mood, stress), physical (demographics and treatment variables) and situational factors (partner variables and fatigue) as predictors of vaginal dryness and performance outcomes at baseline and at various endpoints throughout the study. (Exploratory)
- To explore the characteristics of vaginal atrophy and the relationship between vaginal atrophy and quality-of-life questionnaire responses and exposure to hormonal therapy (tamoxifen, exemestane, anastrozole, or letrozole). (Exploratory)
- To examine the effects of the use of open-label vaginal DHEA gel over 8 weeks in women completing the placebo gel arm of the randomized trial. (Exploratory)
Correlative Research Goals:
- To evaluate the impact of vaginal DHEA on maturation index and pH (select institutions).
- To evaluate the impact of vaginal DHEA on sex steroid concentrations (estradiol, free testosterone, estrone, and DHEA-S) and markers of bone turnover (osteocalcin and bone alkaline phosphatase). (Correlative)
- As part of ongoing research for NCCTG Cancer Control studies, we are banking blood products for future studies. (Correlative)
OUTLINE: This is a multicenter study. Patients are stratified according to current tamoxifen therapy (yes vs no), concurrent aromatase inhibitor use (anastrozole/letrozole vs exemestane vs none), hysterectomy (yes vs no), and cigarette smoking (current vs past vs never). Patients are randomized to 1 of 3 treatment arms, patients receive low dose vaginal DHEA, high dose vaginal DHEA or vaginal placebo gel.
Participants may complete the Profile of Mood States (POMS), the Perceived Stress Scale (PSS), the Fatigue: Vitality subscale of the SF-36, the Vaginal Symptom Quality Questionnaire, the DHEA Side Effect Questionnaire, the Female Sexual Function Index (FSFI), the Sexually Related Intrusive Thoughts - ITS, Impact of Treatment Scale, the Urogenital Atrophy Questionnaire, and the Subject Global Impression of Change at baseline and periodically during study.
- Conditions
- Breast Cancer, Gynecologic Cancer
- Being tested
- prasterone, placebo
- Keywords
- depression, anxiety disorder, cognitive/functional effects, sexual dysfunction, cancer survivor, breast cancer, cervical cancer, fallopian tube cancer, uterine sarcoma, vaginal cancer, vulvar cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian sarcoma, ovarian stromal cancer, primary peritoneal cavity cancer, endometrial cancer
- Medical subject headings
- Breast Neoplasms, Depression, Anxiety Disorders, Sexual Dysfunction, Physiological, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
prasteroneDrug
Applied vaginally
placeboOther
Applied vaginally
| Study group | Role | What they receive |
|---|---|---|
| Arm I low dose DHEA | Experimental | Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. Receives: Drug: prasterone |
| Arm II high dose DHEA | Experimental | Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. Receives: Drug: prasterone |
| Arm III placebo | Placebo comparator | Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks
The primary outcome is severity of the most bothersome vaginal symptom: dryness or dyspareunia. The Vaginal Symptom Measure (VSM) was used to evaluate the severity of vaginal dryness and dyspareunia. The VSM uses a 5- point ordinal response scale; 1="none", 2="mild", 3="moderate", 4="severe" and 5="very severe" to measure the severity associated with vaginal dryness and/or dyspareunia. For each patient, the change in severity was calculated by subtracting the baseline from the week 12 reported score. Therefore, the full range of scores ranges from -4 (greatest decrease in severity) to 4 (greatest increase in severity). A negative score indicates a decrease in severity from baseline, zero indicates no reported affect and positive scores indicate a more severe report at week 12. The primary assessment method will be a comparison of the averages of the changes over time in the severity items for the most bothersome symptom from baseline to 12 weeks (as indicated at baseline).
Measured: At baseline and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jun 2011 (estimated)
- Study startJul 2011
- Primary completionAug 2013
- Study completionNov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 464 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Mayo Clinic
- Responsible party
- Sponsor
- Investigators
- Debra Barton, RN, PhD, AOCN, FAAN, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01376349
- Sponsor's protocol ID
- NCCTG-N10C1
- Other IDs
- NCCTG-N10C1, CDR0000702003, NCI-2011-02677
- Status last verified
- Jan 2019
- First submitted
- 17 Jun 2011
- Last updated
- 7 Feb 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Feb 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial
- ClinicalTrials.gov ID
- NCT01376349
- Acronym / sponsor ID
- NCCTG-N10C1
- Conditions
- Breast Cancer, Gynecologic Cancer
- Keywords
- depression, anxiety disorder, cognitive/functional effects, sexual dysfunction, cancer survivor, breast cancer, cervical cancer, fallopian tube cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 464 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Mayo Clinic
- Study start
- Jul 2011
- Primary completion
- Aug 2013 (actual)
- Study completion
- Nov 2017 (actual)
- First posted
- 20 Jun 2011 (estimated)
- Results
- Posted 25 Aug 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors.
PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
Detailed description
Primary Goal:
- To determine the effectiveness of two doses of daily vaginal prasterone (dehydroepiandrosterone [DHEA]) versus placebo for alleviation of the most bothersome vaginal symptom (vaginal dryness or dyspareunia) over 12 weeks.
Exploratory Goals:
- To evaluate any toxicities arising from DHEA in this patient population. (Exploratory)
- To evaluate the impact of vaginal DHEA on negative sexual thoughts, sexual function and urologic symptoms. (Exploratory)
- To explore the role of psychologic (mood, stress), physical (demographics and treatment variables) and situational factors (partner variables and fatigue) as predictors of vaginal dryness and performance outcomes at baseline and at various endpoints throughout the study. (Exploratory)
- To explore the characteristics of vaginal atrophy and the relationship between vaginal atrophy and quality-of-life questionnaire responses and exposure to hormonal therapy (tamoxifen, exemestane, anastrozole, or letrozole). (Exploratory)
- To examine the effects of the use of open-label vaginal DHEA gel over 8 weeks in women completing the placebo gel arm of the randomized trial. (Exploratory)
Correlative Research Goals:
- To evaluate the impact of vaginal DHEA on maturation index and pH (select institutions).
- To evaluate the impact of vaginal DHEA on sex steroid concentrations (estradiol, free testosterone, estrone, and DHEA-S) and markers of bone turnover (osteocalcin and bone alkaline phosphatase). (Correlative)
- As part of ongoing research for NCCTG Cancer Control studies, we are banking blood products for future studies. (Correlative)
OUTLINE: This is a multicenter study. Patients are stratified according to current tamoxifen therapy (yes vs no), concurrent aromatase inhibitor use (anastrozole/letrozole vs exemestane vs none), hysterectomy (yes vs no), and cigarette smoking (current vs past vs never). Patients are randomized to 1 of 3 treatment arms, patients receive low dose vaginal DHEA, high dose vaginal DHEA or vaginal placebo gel.
Participants may complete the Profile of Mood States (POMS), the Perceived Stress Scale (PSS), the Fatigue: Vitality subscale of the SF-36, the Vaginal Symptom Quality Questionnaire, the DHEA Side Effect Questionnaire, the Female Sexual Function Index (FSFI), the Sexually Related Intrusive Thoughts - ITS, Impact of Treatment Scale, the Urogenital Atrophy Questionnaire, and the Subject Global Impression of Change at baseline and periodically during study.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm I low dose DHEA | Experimental | Drug: prasteroneParticipants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. |
| Arm II high dose DHEA | Experimental | Drug: prasteroneParticipants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. |
| Arm III placebo | Placebo comparator | Other: placeboParticipants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Age ≥ 18 years
- Postmenopausal women with a history of breast or gynecologic cancer (currently no evidence of disease). Note: Postmenopausal status will be determined by the following criteria:
- Significant vaginal complaints. Note: Defined as persistent vaginal dryness and/or pain with intercourse (dyspareunia) of sufficient severity to make a patient desire therapeutic intervention.
- Eligibility questionnaire response must be moderate or worse levels of severity on one of the two symptoms, either dryness or dyspareunia. The protocol contains more information.
- Vaginal symptoms must have been present ≥ 2 months prior to randomization.
Key exclusion criteria (23 listed)
- Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤ 2 months prior to randomization or plans to initiate or discontinue any of these medications during the 12-week study.
- Current diagnosis of an active vaginal infection, if symptoms of vaginal infection, this must be ruled out (ie, foul discharge, fever).
- Concurrent chemotherapy (long term adjuvant herceptin, lapatanib, and/or bevacizumab is allowed.
- Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Water-based lubricants (such as KY jelly) are allowed during sexual intercourse.
- Use of any daily non-hormonal vaginal preparations ≤ 1 week prior to study entry.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| prasteroneApplied vaginally | Drug | Arm I low dose DHEA, Arm II high dose DHEA |
| placeboApplied vaginally | Other | Arm III placebo |
Primary outcome
Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks
Time frame: At baseline and 12 weeks
The primary outcome is severity of the most bothersome vaginal symptom: dryness or dyspareunia. The Vaginal Symptom Measure (VSM) was used to evaluate the severity of vaginal dryness and dyspareunia. The VSM uses a 5- point ordinal response scale; 1="none", 2="mild", 3="moderate", 4="severe" and 5="very severe" to measure the severity associated with vaginal dryness and/or dyspareunia. For each patient, the change in severity was calculated by subtracting the baseline from the week 12 reported score. Therefore, the full range of scores ranges from -4 (greatest decrease in severity) to 4 (greatest increase in severity). A negative score indicates a decrease in severity from baseline, zero indicates no reported affect and positive scores indicate a more severe report at week 12. The primary assessment method will be a comparison of the averages of the changes over time in the severity items for the most bothersome symptom from baseline to 12 weeks (as indicated at baseline).
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Feb 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Debra Barton, RN, PhD, AOCN, FAAN principal investigator
University of Michigan
280 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing prasterone in people with Breast Cancer and Gynecologic Cancer, run by Alliance for Clinical Trials in Oncology at 280 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 280 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Aug 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks (time frame: At baseline and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2019.